As of November 23, Twitter is no longer enforcing its COVID-19 misinformation policy; CDC awards more than $3 billion to strengthen the public health infrastructure and workforce; lecanemab appears to slow the spread of Alzheimer disease but is linked to multiple adverse events, symptoms, and deaths.
As of November 23, Twitter is no longer enforcing its COVID-19 misinformation policy, which has led to more than 11,000 account suspensions and nearly 100,000 pieces of content removed since 2020, Politico reported. Twitter's owner Elon Musk did not formally announce the change, although some users noticed a single sentence added to Twitter’s online rules, saying, “Effective November 23, 2022, Twitter is no longer enforcing the COVID-19 misleading information policy.” This moderation policy update now allows users to spread false information on the virus and vaccines, and experts are worried about the harmful effects this will have on COVID-19 cases and deaths.
The CDC is awarding more than $3 billion to help strengthen the United States' public health infrastructure and workforce, Reuters reported. The funding includes $3 billion from the American Rescue Plan to cover state, local, and territorial health departments across the country. It also includes $140 million from a new appropriation to those jurisdictions and $65 million to 3 public health entities to provide training and technical assistance.
Experimental drug lecanemab appears to slow the spread of Alzheimer disease by removing amyloid from the brain, NPR reported. A study published in The New England Journal of Medicine showed the drug reduced the rate of cognitive decline by 27% in nearly 1800 participants in early stages of Alzheimer disease. In a scale ranging 0-18, participants who received lecanemab infusions scored about half a point better in mental functioning, reflecting a slight but statistically significant difference. However, about 1 in 5 participants who received the treatment experienced an adverse event, including swelling or bleeding in the brain. Some participants also reported headaches, visual disturbances, confusion, and other symptoms, and the drug was linked to 2 deaths.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Managing Vitamin Deficiencies in Celiac Disease With Tailored Nutrition
March 19th 2025Celiac disease can lead to both disease-related and diet-induced vitamin deficiencies, making it crucial for patients to receive tailored nutritional management to ensure adequate nutritional intake.
Read More